The effect of low-dose ketamine compared to morphine on the severity of acute pain in emergency situations: a systematic review and meta-analysis Authors: Jun Zhang, Bin Ma Published: 2025 ABSTRACT BackgroundRecent studies have increasingly investigated the efficacy and safety of ketamine for the management of acute pain in emergency settings and compared it with standard treatments, such as morphine; however, the results remain inconsistent. This updated meta-analysis aimed to investigate the efficacy of low-dose ketamine compared to morphine on the severity of acute pain in emergency situations.MethodsWeb of Science, the Cochrane Library, PubMed, and Scopus were systematically searched from their establishment to June 2, 2025, to identify randomized controlled trials comparing the effect of ketamine with morphine on the severity of acute pain in emergency situations. We used a random-effects model to pool data.ResultsTwenty studies with 2559 participants were included. Compared to morphine, ketamine did not significantly change the numerical rating scale (NRS) score 15 min after administration (standardized mean difference (SMD) (SMD) -0.23, 95% confidence interval (CI) (-0.47, 0.00), I2 = 70.92%), 30 min after administration (SMD − 0.08, 95% CI (-0.23, 0.08), I2 = 55.94%), 45 min after administration (SMD 0.09, 95% CI (-0.16, 0.33), I2 = 69.76%), 60 min after administration (SMD 0.04, 95% CI (-0.16, 0.24), I2 = 74.54%), 90 min after administration (SMD − 0.09, 95% CI (-0.37, 0.19), I2 = 63.86%), and 120 min after administration (SMD − 0.01, 95% CI (-0.18, 0.16), I2 = 34.61%). Similarly, compared to morphine, ketamine did not significantly change the visual analogue scale (VAS) score 15 min, 30 min, and 60 min after administration. The two groups did not significantly differ in terms of complete resolution of pain at 30 min, 60 min, and 120 min after administration and the need for rescue analgesia. Ketamine did not increase the overall risk of adverse events (risk ratio (RR) 1.35, 95% CI (0.87, 2.09), I2 = 71.87%) and nausea (RR 0.99, 95% CI (0.68, 1.44), I2 = 24.94%), but significantly increased the risk of dizziness (RR 1.48, 95% CI (1.08, 2.03), I2 = 42.59%) and emergence phenomenon (RR 19.06, 95% CI (3.77, 96.47), I2 = 0.00%) compared to morphine. In subgroup analysis, intravenous ketamine and lower doses of ketamine (≤ 0.3 mg/kg) were more effective than intranasal ketamine and higher doses of ketamine (more than 0.3 mg/kg) in decreasing the severity of acute pain.ConclusionThere is no significant difference in efficacy between ketamine and morphine in controlling the severity of acute pain, but ketamine faces greater safety issues compared to morphine.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13049-025-01500-5. Introduction Acute pain is the main presentation of a wide range of medical conditions. In many cases, it is also the main reason for seeking medical help or visiting the emergency department [1]. Hospital-wide pain prevalence was found to range from 37.7% to 84%, with a higher prevalence among patients undergoing surgery [1]. In-hospital severe pain prevalence was found to range from 9% to 36% [1]. An observational study reported that in the emergency department of a general hospital, traumatic events were the primary cause of pain in most cases (40.44%), followed by urologic problems (13.52%), abdominal conditions (13.39%), and non-traumatic musculoskeletal pain (7.10%) [2]. The study also reported that only 32.46% of patients received pharmacological therapy for their pain, which may suggest that a higher level of attention should be paid to patients’ pain [2]. Similarly, Berben et al. reported that pain, particularly severe pain, is a highly prevalent problem among injured patients, which receives less or no attention in most cases, and remains insufficiently managed in most patients receiving pain medications [3]. Therefore, timely and effective management of acute and severe pain, a prevalent problem among hospitalized patients, is a topic that deserves more attention. Opioids, such as morphine, have long been recognized as the drugs of choice for the management of acute and severe pain in the emergency department [4]. In the last two decades, ketamine has been increasingly studied for severe pain management in the emergency department [5–9]. The primary studies revealed that ketamine can decrease the dose of morphine for pain management [5]. A meta-analysis of 12 randomized controlled trials indicated that compared to traditional agents used in the intensive care unit (ICU), the use of ketamine provided comparable efficacy in terms of pain severity, mean and cumulative opioid consumption, midazolam consumption, ICU length of stay, and mortality among critically ill patients hospitalized in the ICU [10]. Ketamine was also shown to effectively lower pain severity and morphine dose among patients with cancer; however, it was observed that ketamine performs best for acute pain and offers limited benefits for chronic pain among patients with cancer [11]. The addition of ketamine to morphine in the surgical setting was found to offer a greater reduction in pain severity and decrease the need for opioid consumption [12]. Subsequent studies have increasingly compared the efficacy of ketamine with morphine in head-to-head settings, but their results remain controversial to some extent. Some of them reported that ketamine and morphine provide equal efficacy, whereas others reported the superiority of one of them [6, 9, 13–16]. Therefore, an updated meta-analysis is needed to pool data from previous randomized controlled trials and address the existing inconsistency. In this study, we included a markedly higher number of randomized controlled trials compared to previous meta-analyses [17, 18] and compared the effects of ketamine and morphine on pain severity, the need for rescue analgesia, and complete resolution of pain. Method Search strategy This meta-analysis was registered in PROSPERO (CRD420251065874). This study strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline [19]. The Cochrane Library, Web of Science, PubMed, and Scopus were searched from their establishment to June 2, 2025. The search keywords were as follows: (“ketamine”) [title, abstract, keywords] AND (“morphine”) [title, abstract, keywords] AND (“pain”) [title, abstract, keywords] AND (“RCT” OR “randomized controlled trial” OR “clinical trial”) [title, abstract, keywords]. Supplementary Material 1 presents the search strategy. We also searched the reference list of the identified trials or recent reviews to include more studies. We transferred the identified clinical trials to EndNote 8.0 and deleted duplicate reports. Inclusion and exclusion criteria The inclusion criteria were as follows: (I) study design was a clinical trial or a randomized controlled trial; (II) comparing the efficacy of ketamine with morphine for treating acute pain in emergency situations; (III) reporting at least one of the following efficacy outcomes: NRS score at 15 min, 30 min, 45 min, 60 min, 90 min, and 120 min after administration, VAS score at 15 min, 30 min, and 60 min after administration, complete resolution of pain at 30 min, 60 min, and 120 min after administration, the need for rescue analgesia, and adverse events, including the overall number of those experiencing adverse events, and those experiencing nausea, dizziness, and emergence phenomenon. The exclusion criteria were as follows: (I) observational studies, case reports, case series, or review articles; (II) absence of a ketamine or morphine group; and (III) none of the target outcomes were reported. Data extraction and outcome measures Two authors searched the databases and independently evaluated the eligibility of the identified studies. All differences were addressed via discussion. The authors screened the titles and abstracts to determine the relevance of the identified articles and their compliance with the above-mentioned inclusion and exclusion criteria. Thereafter, the full text of other articles was assessed to determine their eligibility for inclusion. We collected the following data: study characteristics (the first author name, publication year, and country of study), population (sex, age, sample size, type of pain), interventions (doses of drugs and routes of administration), and the outcomes (NRS score at 15 min, 30 min, 45 min, 60 min, 90 min, and 120 min after administration, VAS score at 15 min, 30 min, and 60 min after administration, complete resolution of pain at 30 min, 60 min, and 120 min after administration, the need for rescue analgesia, adverse events, including the overall number of those experiencing adverse events, and those experiencing nausea, dizziness, and emergence phenomenon). Risk of bias assessment Two researchers independently conducted risk of bias assessments, and all differences were resolved through consultation. We used the revised Cochrane risk-of-bias tool for randomized trials (RoB2) to determine the risk of bias for all records. The tool measures the risk of bias based on missing outcome data, randomization process, outcome measurement, selection of the reported results, and deviations from intended interventions, thereby providing an overall risk of bias. One of the following ranks was assigned to each of the domains: some concerns, low risk of bias, and high risk of bias [20]. Statistical analysis For all outcome measures, we extracted mean and standard deviation (SD) from all studies and used Cohen’s D test to calculate SMD and 95% CI. Regarding the need for rescue analgesia, complete resolution of pain at 30 min, 60 min, and 120 min after administration, and adverse events, we used the number of responders and non-responders to calculate the RR. We utilized the chi-square test and I2 statistics to assess heterogeneity between trials, and I2 more than 50% was regarded as high statistical heterogeneity. Stata version 14.0 (StataCorp, TX, USA) and a random-effects model (DerSimonian-Laird) were adopted to calculate the effect sizes. Subgroup analysis Subgroup analysis was conducted based on the route of administration (intranasal vs. intravenous) and dose of administration (more than 0.3 mg/kg vs. less than or equal to 0.3 mg/kg). For the NRS score, we conducted subgroup analysis based on data at 15 min after administration because it was the time point with the greatest difference between ketamine and morphine and with the highest number of effect sizes. For the VAS score, we conducted subgroup analysis based on data at 30 min after administration because at this time point, we could find the highest number of effect sizes in both arms for subgroup analysis. Publication bias The funnel plot and Begg’s and Egger’s tests were used to assess the risk of publication bias. Results Systematic search results We found 139 articles in Web of Science, 191 articles in Scopus, 110 articles in PubMed, and 125 articles in the Cochrane Library. Of 565 records, 156 duplicates were removed and 409 records remained. By screening the titles and abstracts, 350 articles were excluded due to the lack of relevance or incompliance with the inclusion criteria. Next, the full text of the 59 remaining articles was assessed to investigate whether they conformed to the inclusion and exclusion criteria. Twenty randomized controlled trials with 2559 participants were included in this meta-analysis (Fig. 1 and Table 1). Iran (40% of studies), the United States (15% of studies), and Thailand (10% of studies) published the highest number of studies compared to other countries. Canada, France, Israel, Saudi Arabia, Egypt, Malaysia, and Australia contributed one study each. Ketamine was administered via the intranasal route in 5 studies, while intravenously in other studies. Morphine was used orally in one trial, intramuscularly or intravenously in another study, and intravenously in other studies. The mean age of participants ranged from 11.8 years to 77.2 years across studies. The main reasons for administering ketamine or morphine were traumatic limb injury, musculoskeletal pain, and renal colic (Table 1). The adverse events reported in different trials varied, but were generally mild and did not require additional medications or interventions. Dizziness and nausea were the most frequent adverse events reported in original studies. Fig. 1Systematic search flowchart Systematic search flowchart Table 1Study characteristicsFirst author namePublication yearCountry of studySettingAge (year, mean)Females number (percentage)ketamine doseRoute of ketamine administrationDose of morphineRoute of morphine administrationParticipant number in the ketamine groupParticipant number in the morphine groupType of pain/participantsReferencesCornec et al.2024FranceOut-of-hospital analgesia5155.1%20 mg, followed by 10 mg every 5 minIntravenous2 or 3 mg every 5 minIntravenous128123Adult patients with out-of-hospitaltrauma and a verbal pain score equal to or greater than 5 [9]Eddie et al.2024MalaysiaEmergency department of an academic hospital2689%0.3 mg/kg over 15 minIntravenous0.1 mg/kg administered over 5 minIntravenous2731Acute long bone fracture in the emergency department [24]Nelles-McGee et al.2024CanadaGynecology and obstetrics department of an academic hospital26.30%200–500 µg/kg over 2 min repeated every 5 min until appropriate analgesiaIntravenous0.1–0.2 mg/kgOral1414Pain control in first-trimester surgical abortion [25]Kampan et al.2024ThailandEmergency department of an academic hospital75.328.2%0.75 mg/kgIntranasal0.1 mg/kgIntravenous4646Older adults in the emergency department with acute musculoskeletal pain [26]Alshahrani et al.2022Saudi ArabiaEmergency department of an academic hospital29.458.3%0.1 mg/kgIntravenous0.1 mg/kgIntravenous138140Acute painful sickle cell crisis [7]Tongbua et al.2022ThailandEmergency department of an academic hospital73.321.6%0.3 mg/kgIntranasal0.1 mg/kgIntravenous3737Musculoskeletal pain relief among older adults in an emergency department [27]Ziaei et al.2022IranEmergency department of an academic hospital34.168%1.5 mg/kgIntranasal0.1 mg/kgIntravenous5050Flank pain (renal colic) in the emergency department [28]Esfahani et al.2021IranEmergency department of an academic hospitalNot reported81.3%0.1 mg/kgIntravenous0.05 mg/kgIntravenous3637Acute pain control in patients with isolated limb injuries in the emergency department [13]Pouraghaei et al.2021IranEmergency department of a tertiary hospital40.3Not reported1 mg/kgIntranasal0.1 mg/kgIntravenous9589For pain management in patients with renal colic [15]Ali et al.2020EgyptPostoperative department of an academic hospital32.6Not reportedA loading dose of 0.15 mg/kg followed by an infusion at a dose of 2 µg/kg/minIntravenousA loading dose of 0.1 mg/kg, followed by a continuous intravenous infusion at a dose of 1 µg/kg/hIntravenous8080Postoperative pain associated with abdominoplasty [6]Forouzan et al.2019IranEmergency department of an academic hospital33.440%0.3 mg/kgIntravenous0.1 mg/kgIntravenous6868Renal colic pain [29]Jahanian et al.2018IranEmergency department of an academic hospital35.8771.2%0.5 mg/kgIntravenous0.1 mg/kgIntravenous7878Patients with long bone fractures [30]Lubega et al.2018AustraliaEmergency department of an academic hospital11.845.5%1 mg/kgIntravenous0.1 mg/kgIntravenous117119Acute severe vaso occlusive pain in children [14]Motov et al.2018United StatesEmergency department of an academic hospital77.223.3%0.3 mg/kgIntravenous0.1 mg/kgIntravenous3030Acute geriatric pain in the emergency department [8]Mahshidfar et al.2017IranEmergency department of an academic hospital34.383%0.2 mg/kgIntravenous0.1 mg/kgIntravenous150150Acute pain of trauma in emergency department [31]Farnia et al.2016IranEmergency department of an academic hospital3772.5%1 mg/kgIntravenous0.1 mg/kgIntravenous2020Renal colic in the emergency department [16]Shimonovich et al.2016IsraelEmergency department of an academic hospital39.568.3%1.0 mg/kgIntranasal0.1 mg/kg intravenous or 0.15 mg/kg intramuscularIntravenous or intramuscular2451Acute traumatic pain in the emergency department [32]Miller et al.2015United StatesEmergency department of an academic hospital3051%0.3 mg/kgIntravenous0.1 mg/kgIntravenous2421Acute pain in the emergency department [33]Motov et al.2015United StatesEmergency department of an academic hospital35.535.5%0.3 mg/kgIntravenous0.1 mg/kgIntravenous4142Moderate-to-severe acute abdominal, flank, or musculoskeletal pain [34]Majidinejad et al.2014IranEmergency unit of a third-level hospital34.375.7%0.5 mg/kgIntravenous0.1 mg/kgIntravenous6363Pain relief of long bone fractures [35] Table 1Study characteristicsFirst author namePublication yearCountry of studySettingAge (year, mean)Females number (percentage)ketamine doseRoute of ketamine administrationDose of morphineRoute of morphine administrationParticipant number in the ketamine groupParticipant number in the morphine groupType of pain/participantsReferencesCornec et al.2024FranceOut-of-hospital analgesia5155.1%20 mg, followed by 10 mg every 5 minIntravenous2 or 3 mg every 5 minIntravenous128123Adult patients with out-of-hospitaltrauma and a verbal pain score equal to or greater than 5 [9]Eddie et al.2024MalaysiaEmergency department of an academic hospital2689%0.3 mg/kg over 15 minIntravenous0.1 mg/kg administered over 5 minIntravenous2731Acute long bone fracture in the emergency department [24]Nelles-McGee et al.2024CanadaGynecology and obstetrics department of an academic hospital26.30%200–500 µg/kg over 2 min repeated every 5 min until appropriate analgesiaIntravenous0.1–0.2 mg/kgOral1414Pain control in first-trimester surgical abortion [25]Kampan et al.2024ThailandEmergency department of an academic hospital75.328.2%0.75 mg/kgIntranasal0.1 mg/kgIntravenous4646Older adults in the emergency department with acute musculoskeletal pain [26]Alshahrani et al.2022Saudi ArabiaEmergency department of an academic hospital29.458.3%0.1 mg/kgIntravenous0.1 mg/kgIntravenous138140Acute painful sickle cell crisis [7]Tongbua et al.2022ThailandEmergency department of an academic hospital73.321.6%0.3 mg/kgIntranasal0.1 mg/kgIntravenous3737Musculoskeletal pain relief among older adults in an emergency department [27]Ziaei et al.2022IranEmergency department of an academic hospital34.168%1.5 mg/kgIntranasal0.1 mg/kgIntravenous5050Flank pain (renal colic) in the emergency department [28]Esfahani et al.2021IranEmergency department of an academic hospitalNot reported81.3%0.1 mg/kgIntravenous0.05 mg/kgIntravenous3637Acute pain control in patients with isolated limb injuries in the emergency department [13]Pouraghaei et al.2021IranEmergency department of a tertiary hospital40.3Not reported1 mg/kgIntranasal0.1 mg/kgIntravenous9589For pain management in patients with renal colic [15]Ali et al.2020EgyptPostoperative department of an academic hospital32.6Not reportedA loading dose of 0.15 mg/kg followed by an infusion at a dose of 2 µg/kg/minIntravenousA loading dose of 0.1 mg/kg, followed by a continuous intravenous infusion at a dose of 1 µg/kg/hIntravenous8080Postoperative pain associated with abdominoplasty [6]Forouzan et al.2019IranEmergency department of an academic hospital33.440%0.3 mg/kgIntravenous0.1 mg/kgIntravenous6868Renal colic pain [29]Jahanian et al.2018IranEmergency department of an academic hospital35.8771.2%0.5 mg/kgIntravenous0.1 mg/kgIntravenous7878Patients with long bone fractures [30]Lubega et al.2018AustraliaEmergency department of an academic hospital11.845.5%1 mg/kgIntravenous0.1 mg/kgIntravenous117119Acute severe vaso occlusive pain in children [14]Motov et al.2018United StatesEmergency department of an academic hospital77.223.3%0.3 mg/kgIntravenous0.1 mg/kgIntravenous3030Acute geriatric pain in the emergency department [8]Mahshidfar et al.2017IranEmergency department of an academic hospital34.383%0.2 mg/kgIntravenous0.1 mg/kgIntravenous150150Acute pain of trauma in emergency department [31]Farnia et al.2016IranEmergency department of an academic hospital3772.5%1 mg/kgIntravenous0.1 mg/kgIntravenous2020Renal colic in the emergency department [16]Shimonovich et al.2016IsraelEmergency department of an academic hospital39.568.3%1.0 mg/kgIntranasal0.1 mg/kg intravenous or 0.15 mg/kg intramuscularIntravenous or intramuscular2451Acute traumatic pain in the emergency department [32]Miller et al.2015United StatesEmergency department of an academic hospital3051%0.3 mg/kgIntravenous0.1 mg/kgIntravenous2421Acute pain in the emergency department [33]Motov et al.2015United StatesEmergency department of an academic hospital35.535.5%0.3 mg/kgIntravenous0.1 mg/kgIntravenous4142Moderate-to-severe acute abdominal, flank, or musculoskeletal pain [34]Majidinejad et al.2014IranEmergency unit of a third-level hospital34.375.7%0.5 mg/kgIntravenous0.1 mg/kgIntravenous6363Pain relief of long bone fractures [35] Study characteristics Adult patients with out-of-hospital trauma and a verbal pain score equal to or greater than 5 Risk of bias assessment Given their open-label nature, some studies, including those conducted by Cornec et al., Eddie et al., Shimonovich et al., and Miller et al., revealed a high risk of bias based on the revised Cochrane risk-of-bias tool for randomized trials (RoB2) (Supplementary material 2). Other studies did not indicate a substantial risk of bias. In total, 20% of studies were identified to be high-risk, 20% of studies were found to suffer from some concerns, and the remaining studies were found to be low-risk. Meta-analysis We pooled data from 20 studies to compare the effect of ketamine and morphine on acute pain severity. A random-effects model was employed to pool data. Compared to morphine, ketamine did not significantly change the NRS score 15 min (SMD − 0.23, 95% CI (-0.47, 0.00), I2 = 70.92%) (Fig. 2), 30 min (SMD − 0.08, 95% CI (-0.23, 0.08), I2 = 55.94%) (Fig. 3), 45 min (SMD 0.09, 95% CI (-0.16, 0.33), I2 = 69.76%) (Fig. 4), 60 min (SMD 0.04, 95% CI (-0.16, 0.24), I2 = 74.54%) (Fig. 5), 90 min (SMD − 0.09, 95% CI (-0.37, 0.19), I2 = 63.86%) (Fig. 6), and 120 min (SMD − 0.01, 95% CI (-0.18, 0.16), I2 = 34.61%) after administration (Fig. 7). Fig. 2The effect of ketamine compared to morphine on the NRS score at 15 min after administration The effect of ketamine compared to morphine on the NRS score at 15 min after administration Fig. 3The effect of ketamine compared to morphine on the NRS score at 30 min after administration The effect of ketamine compared to morphine on the NRS score at 30 min after administration Fig. 4The effect of ketamine compared to morphine on the NRS score at 45 min after administration The effect of ketamine compared to morphine on the NRS score at 45 min after administration Fig. 5The effect of ketamine compared to morphine on the NRS score at 60 min after administration The effect of ketamine compared to morphine on the NRS score at 60 min after administration Fig. 6The effect of ketamine compared to morphine on the NRS score at 90 min after administration The effect of ketamine compared to morphine on the NRS score at 90 min after administration Fig. 7The effect of ketamine compared to morphine on the NRS score at 120 min after administration The effect of ketamine compared to morphine on the NRS score at 120 min after administration Similarly, compared to morphine, ketamine did not significantly change the VAS score 15 min (SMD 0.29, 95% CI (-0.42, 0.99), I2 = 83.24%), 30 min (SMD 0.40, 95% CI (-0.24, 1.04), I2 = 93.54%), and 60 min (SMD 0.42, 95% CI (-0.14, 0.99), I2 = 91.43%) after administration (Supplementary material 3). Regarding complete resolution of pain, we found that compared to morphine, ketamine did not significantly change the chance of complete resolution of pain at 30 min (RR 1.27, 95% CI (0.70, 2.29), I2 = 0.00%), 60 min (RR 0.96, 95% CI (0.52, 1.76), I2 = 0.00%), and 120 min (RR 0.96, 95% CI (0.52, 1.80), I2 = 0.00%) after administration (Supplementary material 3). Compared to morphine, ketamine did not significantly alter the need for rescue analgesia in the follow-up period (RR 1.08, 95% CI (0.74, 1.58), I2 = 61.90%) (Supplementary material 3). Regarding adverse events, compared to morphine, ketamine did not increase the overall risk of adverse events (RR 1.35, 95% CI (0.87, 2.09), I2 = 71.87%) (Supplementary material 3). Similarly, ketamine did not increase the risk of nausea (RR 0.99, 95% CI (0.68, 1.44), I2 = 24.94%), while the risk of dizziness was significantly increased compared to morphine (RR 1.48, 95% CI (1.08, 2.03), I2 = 42.59%) (Supplementary material 3). Although the emergence phenomenon was reported only by two clinical trials, they showed that compared to morphine, ketamine significantly elevated the risk of emergence phenomenon (RR 19.06, 95% CI (3.77, 96.47), I2 = 0.00%) (Supplementary material 3). Subgroup analysis We first assessed the effect of the route of administration on the effects of ketamine. Subgroup analysis for the NRS score after 15 min of administration indicated that unlike intranasal ketamine administration (SMD − 0.07, 95% CI (-0.28, 0.14), I2 = 0.00%), intravenous ketamine administration (SMD − 0.34, 95% CI (-0.69, -0.00), I2 = 79.22%) led to a significant decrease in the NRS score compared to morphine (Supplementary material 4). In addition, subgroup analysis was conducted for the VAS score after 30 min of administration. The analysis indicated that compared to morphine, intravenous ketamine did not significantly change the VAS score (SMD 0.22, 95% CI (-0.64, 1.09), I2 = 95.24%), but intranasal ketamine was associated with a significant increase in the VAS score (SMD 0.75, 95% CI (0.02, 1.48), I2 = 80.43%). The results of subgroup analysis indicated that intravenous ketamine was more effective than intranasal ketamine in decreasing pain severity (Supplementary material 4). Regarding the dose of administration, a significantly greater decrease in the NRS score ((SMD − 0.25, 95% CI (-0.49, -0.01), I2 = 53.76%) vs. (SMD 0.07, 95% CI (-0.20, 0.33), I2 = 44.28%)) was observed when the dose of ketamine was less than 0.3 or equal to 0.3 mg/kg Supplementary material 4). However, for the VAS score, there was not a significant change between lower doses (less than or equal to 0.3 mg/kg) (SMD 0.49, 95% CI (-1.27, 2.24), I2 = 98.10%) and higher doses (more than 0.3 mg/kg) (SMD 0.35, 95% CI (-0.27, 0.97), I2 = 87.13%). Publication bias The funnel plot exhibited some degree of asymmetry; therefore, Begg and Egger’s tests were employed to assess the risk of publication bias. Both tests indicated no significant risk of publication bias (p-value = 0.11 and p-value = 0.08, respectively) (Supplementary material 5). Discussion This updated meta-analysis included 20 randomized controlled trials with 2559 participants and indicated that compared to morphine, ketamine did not significantly change the NRS score after 15 min, 30 min, 45 min, 60 min, 90 min, and 120 min of drug administration. Similarly, compared to morphine, ketamine did not significantly change the VAS score after 15 min, 30 min, and 60 min of drug administration. The two groups were not significantly different in terms of complete resolution of pain at 30 min, 60 min, and 120 min after administration and the need for rescue analgesia. Regarding safety, we found no significant difference between morphine and ketamine in terms of the overall risk of adverse events and nausea, but ketamine was associated with a significant increase in the risk of dizziness and emergence phenomenon. In subgroup analysis, intravenous ketamine and lower doses of ketamine (≤ 0.3 mg/kg) were more effective than intranasal ketamine and higher doses of ketamine (more than 0.3 mg/kg). Adopting lower doses of ketamine may help improve efficacy and prevent adverse events. Guo et al. conducted a meta-analysis of 15 randomized controlled trials and compared the efficacy of ketamine with morphine for the management of acute pain [17]. They reported that the ketamine group had a significantly lower NRS score 30 min after administration, while the morphine group had a significantly lower NRS score 120 min after administration, suggesting the greater efficacy of ketamine early after administration, but the superiority of morphine 2 h after administration [17]. However, our meta-analysis with 20 randomized controlled trials and 2559 participants showed no significant difference between the two groups at any time point after drug administration. It is also worth noting that Guo et al. adopted weighted mean difference (WMD) for calculating the pooled NRS score and VAS score, but we adopted SMD, which is more appropriate for scoring systems [17]. Similar to our meta-analysis, Guo et al. revealed that intravenous ketamine is superior to intranasal ketamine in reducing the severity of acute pain [17]. Consistent with our findings, a meta-analysis of 4 studies revealed that there is no significant difference between ketamine and morphine as prehospital analgesics for patients with traumatic pain [21]. These findings suggest that intravenous ketamine, particularly low doses of intravenous ketamine, may be more effective than intranasal ketamine and morphine in reducing pain severity. Regarding adverse events, similar to our meta-analysis, the meta-analysis conducted by Guo et al. indicated that compared to morphine, ketamine does not change the overall risk of adverse events or may also lower the risk of adverse events needing intervention [17]. However, with a more detailed analysis, we found that ketamine may increase the risk of dizziness and emergence phenomenon compared to morphine, necessitating more caution. Although the mechanisms underlying the analgesic effects of ketamine seem to be multifactorial and largely unknown, previous studies have reported that the blockade of N-methyl-D-aspartate (NMDA) receptors accounts for a major proportion of the analgesic effects of ketamine [22]. It has also been indicated that the opioid, gamma-aminobutyric acid (GABA), and monoaminergic systems play a less important role in the analgesic effects of ketamine [22]. In addition to ketamine, its metabolites possess analgesic effects, which can help prolong the beneficial effects on pain [22]. Ketamine also possesses anti-depressive properties, which may help prevent the conversion of acute pain to chronic pain [22, 23]. Our findings suggest that there is no difference between the efficacy of ketamine and morphine in terms of controlling acute pain in emergency situations; however, compared to morphine, ketamine may increase the risk of some types of adverse events, such as dizziness and emergence phenomenon. Limitations There are some limitations to our study. First, some studies were open-label and their risk of bias was markedly high, which could potentially affect the accuracy of our results. Second, we detected some methodological differences among studies, which have been delineated in previous sections; however, degrees of methodological difference are common among studies included in a meta-analysis. Specifically, drug dosage and route of administration were different among the included trials. Third, we detected high statistical heterogeneity for some comparisons; therefore, a random-effects model was employed to conduct this meta-analysis. Fourth, some of the included trials had a small sample size; thus, future large-scale multi-center clinical trials are needed to confirm our findings. Conclusion Ketamine was not inferior to morphine in decreasing the severity of acute pain at different time points after administration. There was no significant difference between ketamine and morphine in terms of complete resolution of pain and the need for rescue analgesia. However, some types of adverse events, particularly dizziness and emergence phenomenon, were more common in the ketamine group than in the morphine group. In subgroup analysis, intravenous ketamine and lower doses of ketamine (≤ 0.3 mg/kg) were more effective than morphine, intranasal ketamine, and higher doses of ketamine (more than 0.3 mg/kg). Adopting lower doses of ketamine may help improve efficacy and prevent adverse events. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5